Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019
Executive Summary
The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.
You may also be interested in...
Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT
Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.
US FDA's Ebola Drug Approvals Showcase Efficiencies With Master Protocols
Agency approved Regeneron’s monoclonal antibody cocktail Inmazeb and Ridgeback’s mAB Ebanga on data from a multi-arm, adaptive trial in which several investigational agents were independently compared to a control group. Efficacy for both drugs was demonstrated on a mortality endpoint, with lingering uncertainties to be addressed through postmarketing studies.
COVID-19 Vaccines: A Dose Of Caution From Merck
The global COVID-19 pandemic is prompting an unprecedented effort to develop a vaccine in record-breaking time. But there may be pitfalls in letting optimism run too far ahead of the realities of vaccine development.